BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 12641866)

  • 1. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care outcomes case study: Febrile neutropenia.
    Holdsworth MT; Duncan MH
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs associated with febrile neutropenia in the US.
    Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
    Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas.
    Costa VC; Ferraz MB; Petrilli AS; Pereira CA; Rogerio JW
    Support Care Cancer; 2003 Jun; 11(6):356-61. PubMed ID: 12720070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
    Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
    Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
    Flanigan JA; Yasuda M; Chen CC; Li EC
    Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
    Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
    Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
    Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
    N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective review of gynecologic oncology patients with therapy-induced neutropenic fever.
    McMeekin DS; Gazzaniga C; Berman M; DiSaia P; Manetta A
    Gynecol Oncol; 1996 Aug; 62(2):247-53. PubMed ID: 8751557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between serum levels of MASP-2 and neutropenic febrile attacks in children with leukemia.
    Nazari S; Ebrahimi M; Abdollah Gorji F; Abadi A; Fahimzad A
    Arch Iran Med; 2012 Oct; 15(10):625-8. PubMed ID: 23020538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
    Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
    Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.